Popular Articles

cure me

Pfizer Announces New Phase 1 Data From Two Novel Compounds For Alzheimer's Disease At ICAD Annual Meeting
Pfizer Inc announced today results from two Phase 1 safety studies, one of PF-04360365, a humanized anti-amyloid monoclonal antibody (mAb), and another of dimebon (latrepirdine*) in combination with donepezil HCl tablets, in patients with Alzheimer"s disease.1,2 Based on the Phase 1 study results, PF-04360365 has advanced into Phase 2.3 Dimebon (latrepirdine), being co-developed by Pfizer and Medivation Inc., is in Phase 3 development.4 These data were presented this week at the Alzheimer"s Association 2009 International Conference on Alzheimer"s Disease (ICAD) in Vienna, Austria.
Polygraphy
A Selection Of Opinions And Editorials
The End Of Medical Miracles? - Wall Street Journal
News of the day
Nile Therapeutics CD-NP Clinical Program For Acute Heart Failure Released From Clinical Hold By FDA
Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, received notification from the U.S. Food and Drug Administration (FDA) that the agency has released the Company"s CD-NP development program from clinical hold.
Health Insurance

Global Fund Faces $3B Funding Shortfall

The Global Fund to Fight AIDS, Tuberculosis and Malaria is facing a budget shortfall of about $3 billion, Marcela Rojo, a Global Fund spokesperson, said on Friday, Reuters reports. Rojo said the Global Fund needs $170 million to pay for the programs it committed to supporting last year, and the organization will need between $2.5 billion and $3 billion to maintain and finance programs planned for 2010. "The Global Fund will need a substantially higher amount than the one pledged at the last replenishment in Berlin in 2007 ($10 billion)," Rojo said, adding, "The decisions that are made in the next 18 months will be critical for sustaining the gains achieved in global health so far and further scaling up programmes." According to Reuters, the U.S. "is the largest donor supporting public health programmes through the Global Fund." Since the Global Fund was created in 2002, Washington has pledged more than $4.4 billion to support its programs. "Question marks over funding for the Global Fund"s long-term programmes may raise public health threats, because patients receiving AIDS and tuberculosis drugs need to keep taking the treatment to avoid developing resistance to it," writes Reuters (MacInnis, 7/3). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):